Schrödinger

107 articles with Schrödinger

• Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference

  11/21/2022

  Schrödinger today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - November 18, 2022

  11/18/2022

  Schrödinger, Inc. reported that on November 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 32,165 shares of the company’s common stock to eight newly hired employees, including two newly hired employees based outside of the United States.

• Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference

  11/7/2022

  Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies 13th Annual London Healthcare Conference in London, UK.

• Schrödinger Reports Third Quarter 2022 Financial Results

  11/3/2022

  Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the third quarter of 2022.

• Schrödinger to Announce Third Quarter 2022 Financial Results on November 3

  10/20/2022

  Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2022 financial results on Thursday, November 3, 2022, after the financial markets close.

• 

  Schrödinger, Eli Lilly Strike $425M Small Molecule Deal

  10/7/2022

  Computational technology company Schrödinger announced Thursday it has forged a $425 million drug design collaboration with Eli Lilly.

• Schrödinger Hosts Platform Day

  10/6/2022

  Schrödinger is providing a detailed review of its technology platform, the impact of this platform across a growing portfolio of collaborative and proprietary drug discovery programs, areas for future innovation, and the opportunities for value creation during its Platform Day today, October 6, from 10:00 a.m. - 12:00 p.m. ET.

• Schrödinger to Host Platform Day on October 6, 2022

  9/20/2022

  Schrödinger today announced that the company will host Platform Day in New York City on Thursday, October 6, 2022, beginning at 10:00 AM ET.

• Schrödinger to Present at Citi’s 17th Annual BioPharma Conference

  8/31/2022

  Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that management will participate at Citi’s 17th Annual BioPharma Conference.

• Schrödinger Reports Inducement Grants To Newly Appointed Chief Financial Officer - Aug 18, 2022

  8/18/2022

  Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced the grant of inducement equity awards to the company’s newly appointed chief financial officer, Geoffrey Porges, MBBS.

• Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

  8/18/2022

  Schrödinger, Inc. today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer.

• Schrödinger Reports Second Quarter 2022 Financial Results

  8/4/2022

  Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced financial results for the second quarter of 2022.

• Schrödinger to Announce Second Quarter 2022 Financial Results on August 4

  7/21/2022

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2022 financial results on Thursday, August 4, 2022, after the financial markets close.

• Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor

  6/28/2022

  Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for its MALT1 inhibitor, SGR-1505.

• Schrödinger Convenes Global Educators For Second Annual Educator’s Day

  6/22/2022

  Schrödinger, Inc . (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today will host its second annual Educator’s Day , bringing together K-12 and university educators from across the globe to discuss the growing opportunity for incorporating computational tools in the classroom.

• Schrödinger to Present at Jefferies Healthcare Conference

  6/2/2022

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.

• Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

  5/19/2022

  Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022.

• Schrödinger to Present at Citi Biotech Virtual Co-Panel Day

  5/13/2022

  Schrödinger announced that management will participate at the Citi Biotech Virtual Co-Panel Day.

• Schrödinger Reports First Quarter 2022 Financial Results

  5/4/2022

  Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced financial results for the first quarter of 2022.

• Schrödinger to Announce First Quarter 2022 Financial Results on May 4

  4/20/2022

  Schrödinger will report its first quarter 2022 financial results on Wednesday, May 4, 2022, after the financial markets close.